Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Urology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2011.03.023PMID 21454009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

  2012cited by this paper
• Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long-term oncological, functional, and quality of life results

  2012cited by this paper
• Analysis of early complications of robotic-assisted radical cystectomy using a standardized reporting system.

  2011cited by this paper
• Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis

  2011cited by this paper
• A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

  2010cited by this paper
• Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results.

  2010cited by this paper
• Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.

  2010cited by this paper
• Ileal Neobladder and Its Variants

  2010cited by this paper
• Early complications of cystectomy after high dose pelvic radiation.

  2010cited by this paper
• Robotic-assisted laparoscopic intracorporeal urinary diversion

  2010cited by this paper
• A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder.

  2010cited by this paper
• MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

  2010cited by this paper
• Predicting individual outcomes after radical cystectomy: an external validation of current nomograms

  2010cited by this paper
• European Organization for Research and Treatment of Cancer

  2010cited by this paper
• Incidental prostate cancer at radical cystoprostatectomy: implications for apex‐sparing surgery

  2010cited by this paper
• Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

  2010cited by this paper
• Lessons learned from 1,000 neobladders: the 90-day complication rate.

  2010cited by this paper
• Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.

  2010cited by this paper
• Robotic-assisted laparoscopic intracorporeal urinary diversion.

  2010cited by this paper
• Prevention and management of complications following radical cystectomy for bladder cancer.

  2010cited by this paper
• Individualized seminal vesicle sparing cystoprostatectomy combined with ileal orthotopic bladder substitution achieves good functional results.

  2010cited by this paper
• Detection of circulating tumor cells in patients with urothelial cancer.

  2009cited by this paper
• Complications and mortality after radical cystectomy for bladder transitional cell cancer.

  2009cited by this paper
• Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

  2009cited by this paper
• The oncologic results of laparoscopic radical cystectomy are not (yet) equivalent to open cystectomy

  2009cited by this paper
• Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder

  2009cited by this paper
• Complications following radical cystectomy for bladder cancer in the elderly.

  2009cited by this paper
• Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma.

  2009cited by this paper
• Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.

  2009cited by this paper
• Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma

  2009cited by this paper
• Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

  2009cited by this paper
• Laparoscopic and robotic assisted radical cystectomy for bladder cancer: a critical analysis.

  2008cited by this paper
• Molecular targets and targeted therapies in bladder cancer management

  2008cited by this paper
• The Motion: Seminal-Nerve Sparing Radical Cystectomy is an Efficacious and Safe Treatment for Selected Bladder Cancer Patients

  2008cited by this paper
• Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

  2008cited by this paper
• Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy.

  2008cited by this paper
• Open to debate. The motion: seminal-nerve sparing radical cystectomy is an efficacious and safe treatment for selected bladder cancer patients.

  2008cited by this paper
• Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions.

  2008cited by this paper
• Clinical Results of a Concomitant Boost Radiotherapy Technique for Muscle-Invasive Bladder Cancer

  2008cited by this paper
• Comparison of complications in three incontinent urinary diversions.

  2008cited by this paper
• Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

  2007cited by this paper
• Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy.

  2007cited by this paper
• New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder

  2007cited by this paper
• The rationale for radical cystectomy as primary therapy for T4 bladder cancer

  2007cited by this paper
• Urinary diversion.

  2007cited by this paper
• Outcome of buccal mucosal graft urethroplasty for long and repeated stricture repair.

  2007cited by this paper
• Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.

  2007cited by this paper
• Standards for surgical complication reporting in urologic oncology: time for a change.

  2007cited by this paper
• Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens

  2007cited by this paper
• A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

  2006cited by this paper
• Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution.

  2006cited by this paper
• Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy

  2006cited by this paper
• Long-term results of standard procedures in urology: the ileal neobladder

  2006influential reference
• Trimodality treatment and selective organ preservation for bladder cancer.

  2006cited by this paper
• Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

  2006cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components

  2006cited by this paper
• Is there an indication for frozen section examination of the ureteral margins during cystectomy for transitional cell carcinoma of the bladder?

  2006cited by this paper
• Four years experience in bladder preserving management for muscle invasive bladder cancer.

  2005cited by this paper
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

  2005cited by this paper
• Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.

  2005cited by this paper
• Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

  2005cited by this paper
• Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

  2005cited by this paper
• Cystectomy – Technical Considerations in Male and Female Patients

  2005cited by this paper
• Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

  2004cited by this paper
• Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper?

  2004cited by this paper
• Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older.

  2004influential reference
• Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey

  2004cited by this paper
• Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies.

  2004cited by this paper
• The phase III candidate: can we improve the science of selection?

  2004cited by this paper
• Lymphadenectomy with cystectomy: is it necessary and what is its extent?

  2004cited by this paper
• Surgical complications of urinary diversion

  2004cited by this paper
• Contemporary concepts of radical cystectomy and the treatment of bladder cancer.

  2003cited by this paper
• Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.

  2003cited by this paper
• Editorial: Contemporary Concepts of Radical Cystectomy And The Treatment of Bladder Cancer

  2003cited by this paper
• Can patient selection for bladder preservation be based on response to chemotherapy?

  2003cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.

  2003cited by this paper
• An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma.

  2003cited by this paper
• A Systematic Overview of Radiation Therapy Effects in Urinary Bladder Cancer

  2003cited by this paper
• Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

  2002cited by this paper
• Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy.

  2002cited by this paper
• Surgery versus radiotherapy for muscle invasive bladder cancer?

  2001cited by this paper
• Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

  2001cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

  2000cited by this paper
• Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.

  2000cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper
• Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients.

  1999cited by this paper
• Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.

  1998cited by this paper
• Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall.

  1998cited by this paper
• Bladder preservation by combined modality therapy for invasive bladder cancer.

  1997cited by this paper
• Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time.

  1995cited by this paper
• Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder.

  1995cited by this paper
• Rationale and technique of nerve sparing radical cystectomy before an orthotopic neobladder procedure in women.

  1995cited by this paper
• Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial.

  1994cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

  1989cited by this paper

• Prognostic biomarker PSMD14 facilitates bladder cancer tumorigenesis and progression by regulating Nucleolin-YAP1 axis

  2025cites this paper
• Developing a prediction model in a large case-control study for the early detection of bladder cancer

  2025cites this paper
• Treatment Patterns and Radical Cystectomy Outcomes in Patients Diagnosed With Urothelial Nonmetastatic Muscle‐Invasive Bladder Cancer in the United States

  2025cites this paper
• A nomogram for predicting overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy: a retrospective cohort study

  2025cites this paper
• The hypoxic ECM and neutrophils in MIBC immunotherapy resistance.

  2025cites this paper
• Evaluation of bladder function in children with familial mediterranean fever and outcomes: A retrospective study

  2025cites this paper
• Vitamin D promotes apoptosis and enhances cisplatin sensitivity in bladder cancer cells by inhibiting the Warburg effect through the AKT/mTOR pathway

  2025cites this paper
• Advances in Multifunctional Electronic Catheters for Precise and Intelligent Diagnosis and Therapy in Minimally Invasive Surgery.

  2024cites this paper
• A Propensity Score-Based Comparison regarding Renal, Functional, and Surgical Outcome of Continent Cutaneous Urinary Diversions in Patients with Benign Chronic Bladder Diseases and Patients with Bladder Cancer

  2024cites this paper
• RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2α pathways

  2024cites this paper
• Comparison of the perioperative outcomes of using the Firefly system with indocyanine green during robotic‐assisted cystectomy with urinary diversion

  2024cites this paper
• Clinical upstaging after neoadjuvant chemotherapy impacting eligibility for vaginal-sparing cystectomy: identifying bladder cancer patients who may benefit from interim imaging.

  2024cites this paper
• GI and GU fluoroscopy in common post-op oncologic surgeries: what you need to know about this leaky business!

  2024cites this paper
• Identification of a cisplatin resistant-based prognostic immune related gene signature in MIBC

  2024cites this paper
• Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.

  2023cites this paper
• Long-term renal function following radical cystectomy and ileal conduit creation

  2023cites this paper
• Experience in using the VI-RADS system in assessing the depth of invasion of bladder tumors

  2023cites this paper
• MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer

  2023cites this paper
• 3D laparoscopic radical cystectomy in patients with urinary bladder cancer: a prospective evaluation of safety and efficacy

  2023cites this paper
• Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience

  2023cites this paper
• High MRE11 Expression Level Predicts Poor Survival in Upper Tract Urothelial Carcinomas

  2023cites this paper
• Petromyzontidae‐Biomimetic Multimodal Microneedles‐Integrated Bioelectronic Catheters for Theranostic Endoscopic Surgery

  2023cites this paper
• Modern mRNA-based molecular diagnostics for prediction of urothelial carcinoma behavior

  2023cites this paper
• Melatonin inhibits bladder tumorigenesis by suppressing PPARγ/ENO1-mediated glycolysis

  2023cites this paper
• The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth via the PI3K/AKT Signaling Pathway.

  2023cites this paper
• Anti-Metastatic Effect of Pyruvate Dehydrogenase Kinase 4 Inhibition in Bladder Cancer via the ERK, SRC, and JNK Pathways

  2022cites this paper
• Expression of GLUT4 and FAP in urothelial bladder carcinoma: correlation with angiogenesis and clinicopathological characteristics

  2022cites this paper
• Fatty foods and the risk of bladder cancer: A case-control study.

  2022cites this paper
• A systematic review of prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer

  2022cites this paper
• A Clinicopathological Correlation of Bladder Cancer in Young and Old Patients: Our Experience and Review of Literature

  2022cites this paper
• Value of Prognostic Nutritional Index on Complications After Radical Cystectomy and Ileal Conduit: Retrospective Clinical Research Prognostik Nutrisyonel İ Radikal Sistektomi ve İ leal De ğ eri: Retrospektif Klinik Çal ı ş ma

  2022cites this paper
• Role of microRNAs in regulation of WNT signaling pathway in urothelial and prostate cancers

  2022cites this paper
• Identification of The Immune Subtype Among Muscle-invasive Bladder Cancer Patients by Multiple Datasets.

  2022cites this paper
• The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer

  2022cites this paper
• Robotic radical cystectomy – more precision needed?

  2022cites this paper
• Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDFT1: a review

  2022cites this paper
• CASC5 is a potential cancer-testis gene in human urinary bladder transitional cell carcinoma.

  2021cites this paper
• The Effect of Synergistic Immuno-Photothermal-Nanotherapy ( SYMPHONY ) on Immune Response at Distant Bladder Cancer Tumor Sites Using Murine Window Chamber Model by Ericka

  2021cites this paper
• Solitary cerebellar metastasis from bladder cancer

  2021cites this paper
• Circular RNA circFLNA inhibits the development of bladder carcinoma through microRNA miR-216a-3p/BTG2 axis

  2021cites this paper
• Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model.

  2021cites this paper
• Radical Cystectomy

  2021cites this paper
• Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis.

  2021cites this paper
• An immune cell infiltration-related gene signature predicts prognosis for bladder cancer

  2021cites this paper
• Neo-adjuvant chemotherapy and its anaesthetic implications for surgery—a narrative review

  2021cites this paper
• The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma

  2021cites this paper
• Advancing Radiotherapy for Bladder Cancer: Randomised Phase II Trial of Adaptive Image-guided Standard or Dose-escalated Tumour Boost Radiotherapy (RAIDER).

  2021cites this paper
• Real World Outcomes of Patients with Bladder Cancer: Effectiveness Versus Efficacy of Modern Treatment Paradigms.

  2021cites this paper
• Hypoxia and its Modification in Bladder Cancer: Current and Future Perspectives.

  2021cites this paper
• Emerging role of RNF2 in cancer: From bench to bedside

  2021cites this paper
• Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?

  2021cites this paper
• A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer

  2021cites this paper
• Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer

  2021cites this paper
• Interdisziplinäres Management beim muskelinvasiven Blasenkarzinom

  2020cites this paper
• Developing Biomarkers and New Therapeutic Targets in Muscle Invasive Bladder Cancer

  2020cites this paper
• Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models

  2020cites this paper
• Evaluation of Prognostic Factors for Survival in Bladder Cancer

  2020cites this paper
• Suppressive effects of plumbagin on the growth of human bladder cancer cells via PI3K/AKT/mTOR signaling pathways and EMT

  2020cites this paper
• Comparison of Outcomes Between Radical Radiotherapy and Radical Cystectomy in Muscle Invasive Bladder Cancer in a Cancer Specialized Unit of a Developing Country

  2020cites this paper
• Piceatannol inhibits proliferation and induces apoptosis of bladder cancer cells through regulation of the PTEN/AKT signal pathway.

  2020cites this paper
• Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology

  2020cites this paper
• Magnetism in drug delivery: The marvels of iron oxides and substituted ferrites nanoparticles

  2020cites this paper
• Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density

  2020cites this paper
• Critical role of SOX2–IGF2 signaling in aggressiveness of bladder cancer

  2020cites this paper
• Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress

  2020cites this paper
• Recurrence‐ and progression‐free survival in intermediate‐risk non‐muscle‐invasive bladder cancer: the impact of conditional evaluation and subclassification

  2020cites this paper
• Patient-Derived Urothelial Cancer Xenograft Models: A Systematic Review and Future Perspectives

  2020cites this paper
• Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells

  2020cites this paper
• Atlas of Lymphoscintigraphy and Sentinel Node Mapping: A Pictorial Case-Based Approach

  2020cites this paper
• The clinical study of en bloc transurethral resection with 980 nm laser for treatment of primary non-muscle invasive bladder cancer

  2020cites this paper
• Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer

  2020cites this paper
• Estimation of the effects of radiotherapy treatment delays on tumour responses: A review

  2020cites this paper
• Near Infrared Fluorescence Applications in Urinary Bladder Cancer

  2020cites this paper
• Video Atlas of Intraoperative Applications of Near Infrared Fluorescence Imaging

  2020cites this paper
• Long-term kidney function and mortality after radical cystectomy and ileal conduit formation.

  2020cites this paper
• A Ureteroileal Anastomosis Technique: Simple Modification To The Bricker Technique, A Retrospective Study

  2020cites this paper
• Urothelial cell carcinoma

  2020cites this paper
• The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration

  2020cites this paper
• Ari Alauddin

  2020cites this paper
• Comparative analysis of the clinical effect and safety of Laparoscopic Radical Cystectomy + Orthotopic Ileal Neobladder and Open Surgery

  2020cites this paper
• A Narrative Inquiry into the Adjustment Experiences of Male Bladder Cancer Survivors with a Neobladder

  2020cites this paper
• Etiology of Treatment Delays in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

  2020cites this paper
• LncRNA MAFG-AS1 Promotes the Progression of Bladder Cancer by Targeting the miR-143-3p/COX-2 Axis

  2020cites this paper
• Effect of a Seamless Device for Instillation on Bladder Instillation of Drug After Transurethral Resection of Bladder Tumor

  2020cites this paper
• Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer.

  2019cites this paper
• Involving Patients in the Development and Evaluation of an Educational and Training Experiential Intervention (ETEI) to Improve Muscle Invasive Bladder Cancer Treatment Decision-making and Post-operative Self-care: a Mixed Methods Approach

  2019cites this paper
• Does the Use of a Robot Decrease the Complication Rate Adherent to Radical Cystectomy? A Systematic Review and Meta-Analysis of Studies Comparing Open with Robotic Counterparts

  2019cites this paper
• Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk

  2019cites this paper
• Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung

  2019cites this paper
• Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy

  2019cites this paper
• lncRNA PEG10 promotes cell survival, invasion and migration by sponging miR-134 in human bladder cancer.

  2019cites this paper
• lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer

  2019cites this paper
• Short‐ and long‐term survival has improved after radical cystectomy for bladder cancer in Québec during the years 2000‐2015

  2019cites this paper
• Robot-assisted radical cystectomy with totally intracorporeal urinary diversion: surgical and early functional outcomes through the learning curve in a single high-volume center

  2019cites this paper
• Transurethral-Assisted Transumbilical Laparoendoscopic Single-Site Radical Cystectomy: Initial Short-Term Experience

  2019cites this paper
• lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA‐150

  2019cites this paper
• Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysis

  2019cites this paper
• Bladder Neoplasm

  2019cites this paper
• A Novel Biomarker Based on miRNA to Predict the Prognosis of Muscle-Invasive Bladder Urothelial Carcinoma

  2019cites this paper
• CircRNA circPDSS1 promotes bladder cancer by down-regulating miR-16

  2019cites this paper